3SBio Inc. Receives NMPA Approval for OTC Minoxidil Foam for Male Hair Loss Treatment
3SBio Inc., a leading biopharmaceutical company based in China (HKG: 1530), has announced that it...
3SBio
3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension
3SBio Inc., (HKG: 1530), a leading biopharmaceutical company based in China, has entered into a...
3SBio Subsidiary Gets Green Light for SSGJ-608 Ankylosing Spondylitis Study
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has received...
Sunshine Guojian’s SSGJ-608 Meets Phase III Efficacy Endpoints in Psoriasis Trial
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., a subsidiary of 3SBio Inc. (HKG: 1530), has announced...
3SBio Inc. and CStone Pharmaceuticals Enter Strategic Partnership for Nofazinlimab
China-based 3SBio Inc., (HKG: 1530) has announced a strategic partnership and exclusive licensing agreement with...
Sunshine Guojian Pharmaceutical Gets NMPA Approval for SSGJ-611 Phase II COPD Study
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG: 1530),...
3SBio Inc. Reports H1 2023 Revenue Growth and Expansion in Digital Marketing
China-based 3SBio Inc. (HKG: 1530) has released its financial report for the first half of...
3SBio Inc. Receives NMPA Approval for Nalfurafine Tablets to Treat Hemodialysis-Related Pruritus
China-based 3SBio Inc. (HKG: 1530) has announced receiving marketing approval from the National Medical Products...
3SBio Inc. Initiates Phase III Clinical Study for Thrombopoietin in Chronic Liver Disease Patients
China-based 3SBio Inc. (HKG: 1530) has announced the enrollment of the first patient in a...
Sunshine Guojian Pharmaceutical and Shenyang 3SBio Secure Exclusive Licensing Agreement for Antitumor Programs
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...
Sunshine Guojian Completes Patient Enrollment for SSGJ-611 Phase II Study in Atopic Dermatitis
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has...
3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials
China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859...
Allorion Therapeutics Raises USD 50 Million in Series B Financing to Advance Drug Development
Allorion Therapeutics, a next-generation precision medicine small molecule drug developer based in Guangzhou, reportedly raised...
3SBio’s Nalfurafine Tablets Accepted for Review by NMPA for Chronic Liver Disease
China-based 3SBio Inc. (HKG: 1530) has announced that a clinical trial filing for its nalfurafine...
3SBio Terminates Distribution Agreement with AstraZeneca for Byetta
China-based 3SBio Inc. (HKG: 1530) has announced the termination of a distribution agreement with UK...
3SBio’s Thrombopoietin Study in Pediatric ITP Reaches Primary Endpoint
China-based 3SBio Inc. (HKG: 1530) has announced that its multi-center, randomized, double-blind, placebo-controlled study assessing...
3SBio Receives NMPA Review for Pediatric ITP Thrombopoietin Filing
China-based 3SBio Inc. (HKG: 1530) has announced that the National Medical Products Administration (NMPA) has...
3SBio Inc. Reports H1 2020 Revenue of RMB 3.091B, Net Profit Up 6.19%
China-based 3SBio Inc. (HKG: 1530) reported its H1 2020 financial results, with revenue of RMB...
Cosmo Pharma’s Winlevi Cream Secures Greater China Licensing Deal with 3SBio
Ireland-based Cosmo Pharmaceuticals NV (SWX: COPN) and China’s 3SBio Inc. (HKG: 1530) have signed a...
Sunshine Guojian Pharmaceutical Signs Licensing Deal for Cipterbin ADC Development
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has...